Emerging Immunotherapeutic Agents in Initial Clinical Trials for Head and Neck Malignancies
-
By
-
Harold Nathan Tan
-
Bettzy Stephen
-
Oriol Mirallas
-
Mohamed H. Derbala
-
Israa Salih
-
Lilibeth Castillo
-
Yali Yang
-
Hung Le
-
Lei Kang
-
Heather Lin
-
Joann Lim
-
Ecaterina E. Dumbrava
-
Timothy A. Yap
-
Jordi Rodón
-
Sarina A. Piha-Paul
-
Siqing Fu
-
Stéphane Champiat
-
Neal Akhave
-
Renata Ferrarotto
-
David S. Hong
-
Funda Meric-Bernstam
-
Faye Johnson
-
Aung Naing
-
July 16, 2026
Clinical Scorecard: Emerging Immunotherapeutic Agents in Initial Clinical Trials for Head and Neck Malignancies
At a Glance
| Category | Detail |
|---|
| Condition | Head and neck squamous cell carcinoma (HNSCC) |
| Key Mechanisms | Immune checkpoint inhibitors (ICIs) targeting PD-1, LAG-3, TIM-3, and TIGIT; cytokine-based therapies; cellular therapies; bispecific antibodies. |
| Target Population | Adults (aged ≥18 years) with histologically confirmed recurrent, unresectable, or metastatic HNSCC. |
| Care Setting | Early-phase clinical trials at The University of Texas MD Anderson Cancer Center. |
Key Highlights
- Over 72,000 new cases of HNSCC diagnosed annually in the US.
- Less than 20% of patients achieve long-term survival with current therapies.
- Emerging ICIs aim to overcome immune exhaustion and enhance T-cell function.
- Study evaluates safety and antitumor activity of novel immunotherapy agents.
- Clinical, molecular, and immune biomarkers associated with treatment response explored.
Guideline-Based Recommendations
Diagnosis
- Histologically confirm HNSCC for treatment eligibility.
Management
- Consider ICIs as part of the treatment regimen for recurrent or metastatic HNSCC.
Monitoring & Follow-up
- Assess treatment-related adverse events (TRAEs) and antitumor activity metrics such as ORR, CBR, PFS, and OS.
Risks
- Monitor for immune-related adverse events and assess patient performance status.
Patient & Prescribing Data
Adults with recurrent, unresectable, or metastatic HNSCC not amenable to curative-intent therapy.
Investigational agents include ICIs and other novel therapies targeting immune pathways.
Clinical Best Practices
- Utilize a standardized case report form for data collection.
- Follow Good Clinical Practice guidelines in trial conduct.
- Obtain informed consent from all participants.
Related Resources & Content
